Background: Telithromycin is one of the ketolides, characterised by a 3-keto group instead of L-cladinose and a C11–C12 carbamate link by an alkyl chain to a pyridinum and imidazolium ring side chain. We evaluated in vitro and in vivo antibacterial activities of telithromycin against gynaecological pathogens. Methods: In the vitro study, the antibacterial activity of telithromycin against 180 isolates (isolated in the year 2000) of Streptococcus agalactiae (n = 33), Enterococcus faecalis (n = 22), Neisseria gonorrhoeae (n = 30), Peptostreptococcus anaerobius (n = 20), Finegoldia magna (n = 20), Bacteroides fragilis (n = 25) and Prevotella bivia (n = 30) was compared with that of erythromycin A, clarithromycin, azithromycin, ampicillin and levofloxacin. In the in vivo study, the efficacy of telithromycin was evaluated using experimental intra-abdominal abscesses in mice caused by B. fragilis (minimum inhibitory concentration of telithromycin 0.5 mg/l). Results: In the in vitro study, telithromycin inhibited more than 50% of clinical isolates of S. agalactiae, E. faecalis, N. gonorrhoeae, P. anaerobius, F. magna, B. fragilis and P. bivia at concentrations of 0.016, 0.063, 0.063, 0.032, 0.032, 0.5 and 0.25 mg/l, respectively. Telithromycin inhibited more than 90% of these clinical isolates at concentrations of 0.016, 4, 0.125, 0.063, 0.063, 4 and 1 mg/l, respectively. In the in vivo study, telithromycin inhibited abscess formation and significantly decreased viable cell counts in abscesses in comparison with the untreated group. Conclusions: These in vitro and in vivo antibacterial activities suggest that telithromycin could be a potential candidate for the treatment of bacterial infections complicated by chlamydial infection.
[1]
T. Tamaya,et al.
In vitro antibacterial activities of telithromycin, a new ketolide, against bacteria causing infections in obstetric and gynaecological patients.
,
2000,
The Journal of antimicrobial chemotherapy.
[2]
C. Nord,et al.
In vitro activity of HMR 3647 against anaerobic bacteria.
,
1998,
Journal of chemotherapy.
[3]
T. Tamaya,et al.
Studies on the clinical implications of anaerobes, especiallyPrevotella bivia, in obstetrics and gynecology
,
1998
.
[4]
R. Jones,et al.
Antimicrobial activity of RU-66647, a new ketolide.
,
1997,
Diagnostic microbiology and infectious disease.
[5]
J. Bartlett,et al.
Antimicrobial therapy of experimental intraabdominal sepsis.
,
1975,
The Journal of infectious diseases.
[6]
J. Bartlett,et al.
Experimental Intra-Abdominal Abscesses in Rats: Development of an Experimental Model
,
1974,
Infection and Immunity.